Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 1;12(6):945-948.
doi: 10.21037/hbsn-23-539. Epub 2023 Nov 15.

Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future

Feng Gao  1 , Gang Chen  2   3   4 , Christopher D Byrne  5 , Giovanni Targher  6   7 , Tan To Cheung  8 , Ming-Hua Zheng  9   10   11
Affiliations
Editorial

Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future

Feng Gao et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Metabolic dysfunction-associated fatty liver disease (MAFLD); epidemiology; hepatocellular carcinoma (HCC); metabolic dysfunction-associated steatotic liver disease; nonalcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-539/coif). M.H.Z. serves as an unpaid editorial board member of Hepatobiliary Surgery and Nutrition. G.T. is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. C.D.B. is supported in part by the Southampton NIHR Biomedical Research Centre (NIHR203319), UK. The other authors have no conflicts of interest to declare.

Comment on

  • Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Vitale A, et al. Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21. Gut. 2023. PMID: 34933916

References

    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. 10.1016/j.jhep.2020.03.039 - DOI - PubMed
    1. Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. 10.1097/CM9.0000000000001888 - DOI - PMC - PubMed
    1. Feng G, Valenti L, Wong VW, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023. [Epub ahead of print]. doi: .10.1038/s41575-023-00846-4 - DOI - PubMed
    1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223-38. 10.1038/s41575-020-00381-6 - DOI - PMC - PubMed
    1. Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. 10.1136/gutjnl-2021-324915 - DOI - PubMed